Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.5% Higher – Still a Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) rose 2.5% during mid-day trading on Monday . The stock traded as high as $0.34 and last traded at $0.32. Approximately 48,039,653 shares were traded during trading, a decline of 32% from the average daily volume of 70,497,063 shares. The stock had previously closed at $0.31.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Wednesday, January 1st. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Trading Up 2.2 %

The firm has a market cap of $59.21 million, a PE ratio of -0.01 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The business has a 50-day moving average price of $0.24 and a two-hundred day moving average price of $0.35.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.